

Rec'd PCT/PTO 10 JAN 2005 #2
PCT/GB 2003 / 003040



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

REC'D 12 AUG 2003

WIPO

PCT

**PRIORITY
DOCUMENT**
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH RULE 17.1(a) OR (b)

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.


Signed

Dated 1 August 2003

BEST AVAILABLE COPY

The
Patent

1/77



Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

The Patent Office

Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference	P11085 GB/JM		
2. Patent application number (The Patent Office will fill in this part)	0216147.9		12JUL02 E732798-1 002903 P01/7700 0.00-0216147.9 12 JUL 2002
3. Full name, address and postcode of the or of each applicant (<u>underline all surnames</u>)	Reckitt Benckiser Healthcare (UK) Limited 103-105 Bath Road Slough Berkshire SL1 3UH United Kingdom		
Patents ADP number (if you know it)	08143356001 ✓		
If the applicant is a corporate body, give the country/state of its incorporation	England		
4. Title of the invention	Improvements in or Relating to Medicinal Compositions		
5. Name of your agent (if you have one)	John C. McKnight		
"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)	Reckitt Benckiser plc Group Patents Department Dansom Lane Hull HU8 7DS United Kingdom		
Patents ADP number (if you know it)	8369571001 07800303001		
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it)	Date of filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application (day / month / year)		Date of filing (day / month / year)
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is not named as an applicant, or c) any named applicant is a corporate body. See note (d))	Yes		

Patents Form 1/77

Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description

21 /

Claim(s)

3 /

Abstract

1 /

Drawing(s)

--

0. If you are also filing any of the following, state how many against each item.

Priority documents
Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

One /

Request for substantive examination (Patents Form 10/77)

One /

Any other documents (please specify)

FS2 /

11.

I/We request the grant of a patent on the basis of this application.

Signature

Date

John C. McKnight
John C. McKnight

11 July 2002

12. Name and daytime telephone number of Person to contact in the United Kingdom

John C. McKnight (01482) 583719

Warning
After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

a) If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.

b) Write your answers in capital letters using black ink or you may type them.

c) If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.

d) If you have answered 'Yes' Patents Form 7/77 will need to be filed.

e) Once you have filled in the form you must remember to sign and date it.

f) For details of the fee and ways to pay please contact the Patents Office.

Improvements In and Relating to Medicinal Compositions

The present invention relates to medicinal compositions comprising fibre or saccharide bulking agents.

5

Ingestible fibre- or saccharide-containing compositions for the relief of gastric and digestive dysfunctions are known. Examples of such compositions include granular psyllium husk fibre (ispaghula) intended to be stirred in
10 measured amounts into a volume of liquid, usually water or soft drinks. After stirring, the drinking composition is intended to be quickly imbibed due to the propensity of the ispaghula to absorb water readily and swell to form a viscous gel-like mass. It is the property of water
15 absorption which has the desired characteristic of fibre or saccharide-containing ingestible compositions for gastric and digestive dysfunctions. Once the fibre or saccharide-containing composition has absorbed water to produce the gel-like mass, the mass is relatively
20 insoluble and fibrous, and is transported through the gut quickly with minimal digestion, helping to alleviate constipation and other digestive dysfunctions.

Other forms, such as capsules forms for ingestion, are
25 also available, such capsules being designed to be broken down in the gut, wherein the released fibre or saccharide bulking agent absorbs water from the gut to form the viscous mass.

30 However, for beneficial ease-of-use properties, a particulate form is particularly advantageous to the end user, as this can be stirred into a volume of liquid, for a more pleasant taste, and the granular form of the fibre

or saccharide absorbs water from the gut more quickly than a capsule form. However, there are a number of problems involved in using a granular form of the fibre- or saccharide-containing ingestible compositions.

5

Primarily, it is desirable for the ingestible compositions to disperse easily in liquid, for the user's convenience and/or so that the resultant drink is more palatable and/or easier to swallow. Any new composition must be as
10 good as or, preferably, better than, existing compositions in this respect.

Secondly, the handling of some ingestible fibre- or saccharide-containing compositions is not straightforward.
15 For example in commercial production ispaghula is milled then isopropyl alcohol and a granulating agent polyvinyl pyrrolidone are added. These steps aid handling of the compositions during manufacturing, before the isopropyl alcohol is removed prior to packaging the product for
20 sale. The granulation also aids the dispersion of the ispaghula into a volume of liquid, prior to ingestion. However, the use of the granulating agent and isopropyl alcohol increases the cost of production and the use of the isopropyl alcohol is undesirable from an environmental
25 and a health and safety perspective.

Thus, from the foregoing, it is apparent that there is a need for the provision of an ingestible composition which comprises a fibre or saccharide bulking agent, in which
30 the ingestible composition disperses easily in an aqueous liquid and/or is of improved manufacture.

It has now been determined that an ingestible composition comprising a fibre or saccharide bulking agent, which also includes an ingestible silica in conjunction with an ingestible surfactant, can offer benefit in the manufacture of the ingestible composition, and can increase the rate at which the ingestible composition disperses in water or other ingestible liquid.

Therefore, according to the present invention there is provided an ingestible composition comprising a fibre or saccharide bulking agent, an ingestible silica, and an ingestible surfactant.

The presence of both an ingestible silica and an ingestible surfactant can confer significant, eg synergistic, benefits. For example when the fibre or saccharide bulking agent is ispaghula the ternary composition has outstanding wettability properties, and is easy to manufacture, for example by simple blending.

Suitably the fibre or saccharide bulking agent is a natural ingestible fibre (by which term we include herein fibre extracts). Plant-derived fibre bulking agents are preferred, such as cellulose or derivatives thereof; psyllium husk fibre (ispaghula); or brans such as corn, oat, wheat or rice brans. Animal-derived fibre, fruit-derived fibre and/or synthetic ingestible fibres may also be used.

Particularly preferred as a fibre bulking agent is ispaghula.

The ispaghula may comprise whole ispaghula seeds, but preferably at least part of the ispaghula comprises separated ispaghula seed husks. More preferably the ispaghula comprises at least 50% wt separated ispaghula husks, most preferably at least 95% wt separated ispaghula husks. Suitably the remainder of the ispaghula comprises other seed parts and/or other ispaghula plant materials. In preferred compositions the seed kernels themselves have been substantially removed to leave the husks.

10

If the bulking agent is a saccharide-containing bulking agent it is suitably a polysaccharide, preferably an algin, especially alginic acid or a salt derivative thereof, such as calcium alginate, magnesium alginate, sodium alginate or potassium alginate.

15

Algins may be found in and isolated from various organisms, in particular from algae belonging to the order *Phaeophyceae* and soil bacteria such as *Azotobacter vinelandii* and *Azotobacter crococcum* and from several strains of *Pseudomonas* bacteria. Common algal sources of algin include *Laminaria digitata*, *Ecklonia maxima*, *Macrocystis pyrifera*, *Lessonia nigrescens*, *Ascophyllum nodosum*, *Laminaria japonica*, *Durvillea antartica*, *Durvillea potatorum* and, especially, *Laminaria hyperborea*.

20

Alginic acid is a linear hetero-polysaccharide comprising units of β -D-mannuronic acid and α -L-guluronic acid. Alginic acid may comprise homopolymeric sequences of mannuronic acid, homopolymeric sequences of guluronic acid, and mixed sequences of mannuronic acid and guluronic acid units.

30

Salts of alginic acid used may include alkali metal salts, for example sodium and potassium salts, and ammonium and alkanolamine salts. Alkali metal salts are of particular interest.

5

The term "algins" as used herein includes alginic acid and salts of alginic acid, irrespective of the relative proportion of mannuronic and guluronic units, and is intended to include glycolated or alkoxyated derivatives, especially those derivatised with propylene glycol. However, preferred compounds are not alkoxyated or glycolated.

Suitably the silica is fumed or precipitated synthetic or natural silica. The silica may be amorphous or crystalline.

Suitably the mean particle size of the silica is at least 5nm, preferably at least 10nm.

20

Suitably the mean particle size of the silica is up to 5µm, preferably up to 0.75µm, more preferably up to 0.5µm, and most preferably up to 0.2µm.

The silica material that is used may typically contain 0.1 to 2.5wt% alumina (Al_2O_3), preferably 0.5 to 2wt% alumina, and most preferably about 1wt% alumina, based on the weight of the silica.

One suitable silica material is Syloid 244 which is amorphous silica, has a mean particle size of about 3µm and is provided by W R Grace & Co. Another suitable

silica materials is Silox 15, also from W R Grace & Co., and which has a mean particle size of about $4\mu\text{m}$.

Another suitable silica material is Huber Zep 49 which is
5 amorphous silica from J M Huber Corporation and contains about 1 wt% alumina.

Another suitable silica is Aerosil 200 from Degussa Company. It contains less than 0.05 wt% alumina and has a
10 mean particle size of 12 nm.

Preferably the silica is colloidal silica, and a preferred silica is a colloidal silica which is sold under the trade mark CAB-O-SIL, by Cabot Inc, USA.

15 Suitably the specific surface area of the silica is at least $50\text{m}^2 \text{g}^{-1}$, preferably at least $150\text{m}^2 \text{g}^{-1}$.

Suitably the specific surface area of the silica is up to
20 $400\text{m}^2 \text{g}^{-1}$, preferably up to $300\text{m}^2 \text{g}^{-1}$ most preferably up to $200\text{m}^2 \text{g}^{-1}$.

Suitably the silica is present in the ingestible composition in an amount at least 0.01wt%, preferably at
25 least 0.05wt%, more preferably at least 0.1wt% and most preferably at least 0.25wt%, of the total weight of the ingestible composition.

Suitably the silica is present in the ingestible
30 composition in an amount up to 5wt%, preferably up to 2wt%, more preferably up to 1wt%, and most preferably up to 0.6wt%, of the total weight of the ingestible composition.

Preferably the ingestible surfactant is a polyethylene-, polypropylene-, or polyoxyethylene-based surfactant. Suitable polyethylene or polyoxyethylene-based surfactants
5 include polyethylene glycols and polyoxyethylene sorbitan fatty acid esters (polysorbates).

Suitable polyethylene glycols have a molecular weight of between 200 and 40,000, preferably between 200 and 1,000,
10 and more preferably between 200 and 600. Suitable polyethylene glycols include MACROGOLD and MACROGOLUM polyethylene glycols sold by ICI Surfactants, UK. Other suitable surfactants include polyoxyethylene monostearates and glycerol polyethylene glycol oxystearates.

15 Suitably the surfactant is present in the ingestible composition in an amount at least 0.01wt%, preferably at least 0.05wt%, more preferably at least 0.1wt%, and most preferably at least 0.2wt%, of the total weight of the
20 ingestible composition.

Suitably the surfactant is present in the ingestible composition in an amount up to 5wt%, preferably up to 3wt%, more preferably up to 2wt% and most preferably up to
25 1wt%, of the total weight of the ingestible composition.

When the surfactant is polyethylene glycol it is preferably present in an amount at least 0.1wt%, more preferably at least 0.3wt%, of the total weight of the
30 ingestible composition.

When the surfactant is polyethylene glycol it is preferably present in an amount up to 2wt%, more

preferably up to 1.5wt%, of the total weight of the ingestible composition.

5 When the surfactant is a polyoxyethylene sorbitan fatty acid ester it is preferably present in an amount at least 0.01wt%, more preferably at least 0.05wt%, and most preferably at least 0.08wt%, of the total weight of the ingestible composition.

10 When the surfactant is a polyoxyethylene sorbitan fatty acid ester it is preferably present in an amount up to 2wt%, more preferably up to 1wt%, and most preferably up to 0.5wt%, of the total weight of the ingestible composition.

15 The percentages stated represent the total complement of the silica and surfactant, that is, summated if there is more than one silica or surfactant in the composition.

20 The ingestible composition may further comprise ingestible co-ingredients such as a bicarbonate for example sodium bicarbonate, an ingestible acid, for example citric acid, a flavouring, or a colouring, for example.

25 Preferably the ingestible composition does not contain a granulating agent.

Most preferably the ingestible composition does not contain polyvinyl pyrrolidone.

30 Preferably the ingestible composition does not contain any residue of polyvinyl alcohol.

Suitably the composition is provided in a particulate solid form, for example as a powder or flakes, intended to be mixed with water, prior to ingestion by a user. Alternatively the composition may be provided as a capsule
5 for dispersal in a liquid, for drinking by a user. Preferably the composition is provided in a particulate form.

In accordance with a second aspect of the present
10 invention there is provided a method of making an ingestible composition comprising a fibre or saccharide bulking agent, an ingestible silica, and an ingestible surfactant, the method comprising the step of blending the fibre or saccharide bulking agent with the ingestible
15 silica and the ingestible surfactant.

Preferably no isopropyl alcohol is used in the manufacture.

20 More preferably no solvent of any type is used in the manufacture.

Preferably no polyvinyl pyrrolidone is used in the manufacture.

25 More preferably no granulating agent of any type is used in the manufacture.

The fibre or saccharide bulking agent may be milled prior
30 to the blending step, suitably to a mean particle size in the range 250-450 μ m.

Preferably the method does not include the granulation of the bulking agent.

5 The fibre or saccharide bulking agent may be subjected to a sterilization step prior to the blending step. Irradiation may employ steam or, preferably, a radioactive source, for example a γ -radiation source, for example from a Cobalt-60 or Caesium-137 source. A suitable radiation dosage is up to 13 kGy, preferably 5-10 kGy.

10

The invention will now be described by way of example in which the following materials are used throughout:

15 Ispaghula - Ispaghula husk material obtained from *Plantago ovata*, broken down to enable the seed kernels to be removed. The material was dried, irradiated with γ -radiation from a Caesium-137 source at a dosage rate of about 7 kGy, as described in PCT/GB01/02040, and milled to a mean particle size of 300-400 μ m.

20

CAB-O-SIL (Trade Mark) - A colloidal silica having a specific surface area in the range 175-225m²g⁻¹ manufactured by Cabot Inc, USA.

25 TWEEN 60 (Trade Mark) - A polyoxyethylene sorbitan fatty acid ester, manufactured by ICI.

TWEEN 80 (Trade Mark) - A polyoxyethylene sorbitan fatty acid ester, manufactured by ICI.

30

Propylene glycol.

Cremophore RH40 - Glycerol polyethylene glycol oxysterate, manufactured by BASF.

Pricerine - Porcine glycerine, supplied by Uniquema.

5

PEG 200 - Polyethylene glycol, molecular weight approximately 200, manufactured by Clariant.

10 Liquid surfactants were added slowly to the ispaghula as it was being mixed in a domestic-style MAGIMIXER (Trade Mark). Mixing was continued until the ispaghula appeared evenly covered (dampened).

15 Solid surfactants were ground in a pestle and mortar and then added to the ispaghula and placed in an oven (60-70°C) for 30 minutes. The samples were then quickly blended in the MAGIMIXER as above.

20 To the ispaghula blended with surfactant as described above was added a colloidal silica sample (CAB-O-SIL) in an attempt to dust the samples dry and improve flow characteristics (but also - as will be seen - with the unexpected result that the wetting characteristics of the final product were greatly improved).

25

No granulation step took place; no granulating agent was used.

Test methods

1. Wettability (dispersion in water)

5

This was the most important test used to assess the effectiveness of each treatment and simply involved slowly spreading an amount of the formulation containing 3.5g ispaghula onto the surface of 150ml of cold tap water contained in a 200ml Pyrex beaker, and recording the time taken for all the material to become fully wetted without using any agitation to quicken the process.

2. Water absorbency/swell volume

15

This test determines the swell volume (ml) or ability of a product to take up water. This is a key property for the mechanism of action of ispaghula, and hence disruption/reduction to this effect would certainly impact on efficiency.

20

The method is as follows:

Add 1g of ispaghula (or the equivalent wt of product containing 1g ispaghula) to 100ml of tap water in a 100ml measuring cylinder, mix thoroughly by shaking and allow to stand. At 1 and 2 hours mix again by gentle inversion, and allow to stand for a further 2 hours. At the end of this period (4 hours from start), record the level of mucilage/gel in the measuring cylinder. Typically, this will be 40-50ml per gramme of ispaghula.

30

3. Gel/flow rate on hydration

This method is used to gain an insight into the rate of gel/mucilage formation. Although gelling is an important attribute, the initial onset has been delayed in ingestible ispaghula compositions to allow the consumer to ingest it, over a period of a few minutes, as a palatable drink.

A weight of sample containing 3.5g ispaghula is mixed into 150ml cold tap water in a 200ml beaker. At 5 minute intervals after making up, the time taken for 100ml of the sample to run through a Flow Cup (No. 5) viscometer is recorded. This is basically a brass cup which holds exactly 100ml, with a tapered bottom leading to a standard-sized hole. As a sample gels, then the time taken for 100ml to flow through increases.

4. Carr's Index

20

Carr's index is a measurement of bulk density of pharmaceutical powders, measured in a Copley Erweka Tapped Volumeter, model SVM-22. Powder is placed in a vertical cylinder which is "tapped" in the machine to aid the settlement of the powder, and the percentage change in volume measured, over the predetermined test period/regime, identical for each sample.

Example 1

30

In this series of tests the wetting ability of ternary ispaghula + PEG 200 + CAB-O-SIL compositions was assessed, and compared with non-ternary compositions. The

wettability was measured after 5 minutes, 16-24 hours and 8 days; there is reason from work on other compositions to believe that wettability can decrease as the interval from manufacture increases.

5

As will be seen, there were three replicates. All three results are given in Tables 1-3 below.

10 In each test the measurement was of time (secs) for a dose of treated ispaghula (3.5g) to disperse.

Tables 1-3

PEG 200 + CAB-O-SIL 5 mins after manufacture

15

PEG 200 levels (wt%)	CAB-O-SIL levels (wt%)	
	0.3	0.5
0.4	5,5,5	7,5,6
0.8	7,8,7	6,5,5
1.2	6,4,4	6,7,7

Comparisons: no PEG 200, no CAB-O-SIL: 270, 310, 330
 no PEG 200, 0.3 wt% CAB-O-SIL: 165, 170, 165
 0.4 wt% PEG 200, no CAB-O-SIL: 120, 130, 135

PEG 200 + CAB-O-SIL 16-24 hours after manufacture

	CAB-O-SIL levels (wt%)	
PEG 200 levels (wt%)	0.3	0.5
0.4	6,6,6	7,5,7
0.8	20,20,20	6,5,6
1.2	11,12,11	12,11,12

- 5 Comparisons: no PEG 200, no CAB-O-SIL: not measured
 no PEG 200, 0.3 wt% CAB-O-SIL: 330, 330, 350
 0.4 wt% PEG 200, no CAB-O-SIL: 305, 320, 320

PEG 200 + CAB-O-SIL 8 days after manufacture

10

	CAB-O-SIL levels (wt%)	
PEG 200 levels (wt%)	0.3	0.5
0.4	11,12,11	10,6,7
0.8	25,25,30	8,8,8
1.2	22,30,26	15,17,15

- Comparisons: no PEG 200, no CAB-O-SIL: 310, 300, 280
 no PEG 200, 0.3 wt% CAB-O-SIL: 1800, 1200, 1740
 0.4 wt% PEG 200, no CAB-O-SIL : 470, 480, 510

15

Example 2

20 This series of tests were as Example 1, but used TWEEN 80 instead of PEG 200, and different time intervals. In

these tests ispaghula alone was not tested. The results are given in Tables 4-6 below. Again, in each test the measurement was of time (secs) for a dose of treated ispaghula (3.5g) to disperse (n=3).

5

Tables 4-6

TWEEN 80 + CAB-O-SIL 5 mins after manufacture

TWEEN 80 levels (wt%)	CAB-O-SIL levels (wt%)	
	0.3	0.5
0.09	21,16,17	20,17,20
0.14	7,7,8	8,5,8
0.20	4,4,5	4,4,4

10

Comparisons: no TWEEN 80, no CAB-O-SIL: not measured
 no TWEEN 80, 0.3 wt% CAB-O-SIL: 180, 215, 225
 0.09wt% TWEEN 80, no CAB-O-SIL : 75, 80, 75

15 TWEEN 80 + CAB-O-SIL 72 hours after manufacture

TWEEN 80 levels (wt%)	CAB-O-SIL levels (wt%)	
	0.3	0.5
0.09	25,25,30	30,22,25
0.14	10,13,11	10,10,9
0.20	6,5,4	4,5,5

Comparisons: no TWEEN 80, no CAB-O-SIL: not measured
 no TWEEN 80, 0.3 wt% CAB-O-SIL: 495, 450, 480
 0.09wt% TWEEN 80, no CAB-O-SIL : 63, 70, 60

20

TWEEN 80 + CAB-O-SIL 7 days after manufacture

	CAB-O-SIL levels (wt%)	
TWEEN 80 levels (wt%)	0.3	0.5
0.09	36,27,32	35,35,35
0.14	10,10,12	10,9,8
0.20	7,7,6	4,5,5

- 5 Comparisons: no TWEEN 80, no CAB-O-SIL: not measured
no TWEEN 80, 0.3 wt% CAB-O-SIL: 735, 795, 930
0.09wt% TWEEN 80, no CAB-O-SIL : 75, 67, 78

Again the results for the ternary system are remarkable,
10 much better than either binary system.

Example 3

This test was used primarily to assess long term
15 wettability properties. Obviously such properties are
extremely important for a commercial product.

As before, each experiment employed 3.5g of ispaghula in
the composition, except that for the swell volume test 1g
20 of composition was used.

The compositions were placed in a cycling oven, cycling
between 4°C and 30°C. The samples were tested immediately
on preparation, after 5 weeks incubation in the cycling
25 oven, and after 3 months incubation the cycling oven. As
an exception, compositions including CAB-O-SIL and PEG 200

were tested immediately and after 9 weeks incubation only.
The results of the experiment are shown in Table 7.

Table 7

Storage conditions - Cycling oven (4°C/30°C)

	Initial samples				5 week samples		3 month samples	
Composition	Carrs Index (n=2)	Swell Vol (ml) (n=2)	Wettability times (secs)	Flow cup after 15 min (secs)	Swell Vol (ml) (n=2)	Wettability times (secs)	Flow cup after 15 min (secs)	
Untreated Ispaghula			270					
+ 0.16wt% TWEEN 80 + 0.08wt% CAB-O-SIL	9	40	23	45	44	19	35	37 19 61
+ 0.16wt% TWEEN 60 + 0.08wt% CAB-O-SIL	9	40	20	25	44	19	52	42 22 52
+ 0.4wt% Propylene glycol + 0.08wt% CAB-O-SIL	6	40	44	25	44	60	18	43 81 59
+ 1.2wt% Cremophore + 0.24wt% CAB-O-SIL	7	40	25	25	41	19	33	44 32 46
+ 0.4wt% Pricerine + 0.4wt% CAB-O-SIL	7	41.5	50	35	45	120	21	41 211 62
+ 0.56wt% PEG 200 + 0.24wt% CAB-O-SIL	9	41	15	35				47 27 48

The results show that the addition of all of the tested combinations of ingestible silica in combination with an ingestible surfactant, substantially reduces the time taken for the ispaghula to disperse in a 150ml beaker of cold water (wettability). The wettability time is significantly reduced on initial testing and remains reduced through the 5 week samples and the 3 month samples.

10 In particular, polyethylene glycol and TWEEN in combination with CAB-O-SIL show a marked ability to reduce the wettability time of untreated ispaghula husk compared to other combinations of surfactant with CAB-O-SIL. The results therefore indicate that ingestible compositions
15 comprising surfactant plus CAB-O-SIL mixed with ispaghula husk are also shelf stable at ambient temperatures (between 4°C and 30°C) over a sustained period of time.

Example 4

20

The tests corresponded to those of Example 3 but the compositions were tested by incubating at 40°C in an incubating oven. The samples were tested immediately on preparation, after 5 weeks incubation and after 3 months
25 incubation. As an exception, compositions containing CAB-O-SIL and PEG 200 were tested immediately and after 9 weeks incubation only. The results of the experiment are shown in Table 8.

Table 8

Storage conditions: 40°C

Composition	Initial samples				5 week samples				3 month samples			
	Carrs Index (n=2)	Swell Vol (ml) (n=2)	Wettability times (secs)	Flow cup after 15 min (secs)	Swell Vol (ml) (n=2)	Wettability times (secs)	Flow cup after 15 min (secs)	Swell Vol (ml) (n=2)	Wettability times (secs)	Flow cup after 15 min (secs)	Swell Vol (ml) (n=2)	Wettability times (secs)
Untreated Ispaghula			270									
+ 0.16wt% TWEEN 80 + 0.08wt% CAB-O-SIL	9	40	23	45	44	20	18	46	17	40		
+ 0.16wt% TWEEN 60 + 0.08wt% CAB-O-SIL	9	40	20	25	44	22	21	50	16	31		
+ 0.4wt% Propylene glycol + 0.08wt% CAB-O-SIL	6	40	44	25	42	85	23	47	110	28		
+ 1.2wt% Cremophore + 0.24wt% CAB-O-SIL	7	40	25	25	41	20	45	37	26	30		
+ 0.4wt% Pricerine + 0.4wt% CAB-O-SIL	7	41.5	50	35	43	180	35	50	364	41		
+ 0.56wt% PEG 200 + 0.24wt% CAB-O-SIL	9	41	15	35				47	26	23		

9 weeks storage

Claims

1. An ingestible composition comprising a fibre or saccharide bulking agent, an ingestible silica, and an ingestible surfactant.
 2. An ingestible composition as claimed in claim 1 wherein the composition comprises a plant-derived fibre bulking agent selected from: cellulose or a derivative thereof; ispaghula; or a bran.
 3. An ingestible composition as claimed in claim 1 or 2 wherein the fibre bulking agent is ispaghula.
 4. An ingestible composition as claimed in claim 1 wherein the bulking agent is a polysaccharide-containing bulking agent comprising an algin.
 5. An ingestible composition as claimed in any preceding claim wherein the particle size of the silica is between 5nm and 5 μ m.
 6. An ingestible composition as claimed in any preceding claim wherein the specific surface area of the silica is between 50 and 400gm⁻².
 7. An ingestible composition as claimed in any preceding claim wherein the silica is present in an amount of between 0.01wt% and 5wt% of the total weight of the ingestible composition.
 8. An ingestible composition as claimed in any preceding claim, wherein the ingestible surfactant is a
-

polyethylene-, polypropylene-, or polyoxyethylene-based surfactant.

9. An ingestible composition as claimed in claim 8 wherein the polyethylene-based surfactant is a polyethylene glycol.

10. An ingestible composition as claimed in claim 9 wherein the polyethylene glycol has a molecular weight of between 200 and 40,000, preferably between 200 and 1,000.

11. An ingestible composition as claimed in claim 8 wherein the polyoxyethylene-based surfactant is a polyoxyethylene sorbitan fatty acid ester.

12. An ingestible composition as claimed in claim 8, wherein the surfactant is a polyoxyethylene monostearate or a glycerol polyethylene glycol oxystearate.

13. An ingestible composition as claimed in any preceding claim wherein the ingestible surfactant is present in an amount of between 0.01wt% and 5wt% of the total weight of the ingestible composition.

14. An ingestible composition as claimed in claim 13 wherein the ingestible surfactant is polyethylene glycol and is present in an amount of between 0.1wt% and 2wt% of the total weight of the ingestible composition.


15. An ingestible composition as claimed in claim 13 wherein the surfactant is a polyoxyethylene sorbitan fatty acid ester and is present in an amount of between 1wt% and 2wt% of the total weight of the ingestible composition.

16. A method of making an ingestible composition comprising a fibre or saccharide bulking agent, an ingestible silica, and an ingestible surfactant, the method comprising the step of blending the fibre or saccharide bulking agent with the ingestible silica and the ingestible surfactant; preferably without the employment of isopropyl alcohol or more preferably of any solvent; and preferably without the employment of polyvinyl pyrrolidone or more preferably of any granulating agent.

17. An ingestible composition or its manufacture substantially as described herein.

AbstractImprovements In and Relating to Medicinal Compositions

The present invention provides an ingestible composition comprising a fibre or saccharide bulking agent, an ingestible silica, and an ingestible surfactant. The provision of the silica and the surfactant provides a synergistic benefit in the dispersal of the bulking agent in water thus making it easier and/or quicker to obtain an imbibable liquid. The bulking agent may be ispaghula, a natural material of benefit in promoting good bowel function.



THE PATENT OFFICE
04 AUG 2003
Received in Patents
International Unit
